Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Other Non-Current Assets (2023 - 2025)

Kura Oncology (KURA) has disclosed Other Non-Current Assets for 3 consecutive years, with $14.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Other Non-Current Assets rose 85.38% to $14.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $14.5 million, a 85.38% increase, with the full-year FY2025 number at $14.5 million, up 85.38% from a year prior.
  • Other Non-Current Assets was $14.5 million for Q4 2025 at Kura Oncology, up from $13.8 million in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $14.5 million in Q4 2025 to a low of $210000.0 in Q1 2023.
  • A 3-year average of $7.6 million and a median of $7.8 million in 2024 define the central range for Other Non-Current Assets.
  • Biggest YoY gain for Other Non-Current Assets was 3550.48% in 2024; the steepest drop was 3.2% in 2024.
  • Kura Oncology's Other Non-Current Assets stood at $7.6 million in 2023, then increased by 3.2% to $7.8 million in 2024, then surged by 85.38% to $14.5 million in 2025.
  • Per Business Quant, the three most recent readings for KURA's Other Non-Current Assets are $14.5 million (Q4 2025), $13.8 million (Q3 2025), and $10.6 million (Q2 2025).